Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-16.67% - - 4.97K
+0.42%-2.67%+20.78%+10.60% 216B
-0.83%-2.92%-3.65%-19.90% 142B
+1.68%-1.27%-17.69%+38.53% 138B
-0.38%+0.41%-50.12%+2.41% 74.53B
+0.23%-2.73%+16.35%+18.96% 52.34B
+0.87%-0.56%-16.64%-13.49% 50.28B
+0.05%-0.58%+25.79%+24.63% 41.93B
-0.71%-2.25%+40.18%+50.25% 40.06B
+0.98%+0.73%+0.15%+7.20% 32.69B
Average -1.49%-0.52%+1.68%+13.24% 87.63B
Weighted average by Cap. +0.20%-1.16%+0.66%+10.84%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
-